ArticleScientific reports2026
Objective-function-guided automated VMAT planning reduces OAR dose, low-dose exposure, and inter-planner variability in breast radiotherapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents and evaluates an automated volumetric modulated arc therapy (VMAT) planning framework for breast cancer based on objective function value (OFV)-guided optimization. The primary objective is to systematically improve organ-at-risk sparing through automated and reproducible optimization of planning constraints while maintaining clinically acceptable target coverage. An OFV-guided optimization workflow was empirically developed using a separate sensitivity dataset and subsequently evaluated in 20 clinical breast cancer patients (13 left-sided, 7 right-sided). The automated Python-based framework iteratively adapts MaxEUD constraints during optimization until dose metrics converge, without manual intervention. Automatically generated plans were compared to clinically delivered VMAT plans using target coverage, dose-volume metrics, and monitor units as a surrogate for delivery efficiency. The automated approach consistently achieved significant reductions in mean organ doses and low-dose volumes (e.g., [Formula: see text], [Formula: see text]) while preserving PTV coverage. Mean heart dose decreased from [Formula: see text] Gy to [Formula: see text] Gy for left-sided cases and from [Formula: see text] Gy to [Formula: see text] Gy for right-sided cases ([Formula: see text]). Significant dose reductions were also observed for the ipsilateral lung, contralateral lung, and contralateral breast, accompanied by a 16.9 % reduction in monitor units ([Formula: see text]) and reduced inter-patient variability. In contrast, no statistically significant difference was observed for lung [Formula: see text]. In conclusion, OFV-guided VMAT optimization enables reproducible and systematic improvement of organ-at-risk sparing in breast radiotherapy. By reducing organ doses, low-dose burden, monitor units, and inter-patient variability without compromising target coverage, the proposed framework could provide a robust and standardized baseline for clinical VMAT planning and a consistent foundation for future data-driven and machine-learning-based optimization approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.